@camilapayano1: Hair-Recovery Cytokine Booster #refilled #hairloss #hairtok #kbeauty #playlab @Refilled

Camila Payano
Camila Payano
Open In TikTok:
Region: DO
Tuesday 07 October 2025 05:06:55 GMT
38238
1588
21
34

Music

Download

Comments

ornem06
One ♥️ :
Me interesa yo estoy así perdiendo todo el pelo
2025-10-10 21:44:26
3
marlenybaez0
marleny :
Como le llaman al producto corazón?
2025-10-15 00:51:14
0
marferrer96
marferrer96 :
Es súper bueno ❤️❤️❤
2025-10-07 16:46:29
1
lucygarcia87
Lucy Garcia :
ni veo el nombre amiguita
2025-10-11 00:03:33
1
edita.altagracia6
Edita Altagracia Rodrigez :
a cómo
2025-10-10 23:48:39
0
lucygarcia87
Lucy Garcia :
así estoy no me wuito um moñito
2025-10-11 00:01:49
1
dios.conmigo_100
Ela :
💖💖💖
2025-10-08 04:44:05
1
rusbel.santana
rusbel Santana :
🥰🥰🥰🥰🥰🥰🥰🥰
2025-10-14 23:34:31
0
ricardo.gonzales643
Ricardo Gonzales :
🥰
2025-10-14 10:49:55
0
user145220681250
woudelinemecrilus :
🤣🤣🤣😂🤣🤣🤣🤣🤣
2025-10-15 02:06:12
0
bergermain
bergermain :
🥰🥰
2025-10-10 19:04:13
1
lucia2pc
Lu🎀 :
impresionante
2025-12-15 01:32:05
0
To see more videos from user @camilapayano1, please go to the Tikwm homepage.

Other Videos

Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close.   Note: I have not been compensated in any way for this post/interview.  #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About